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Solar radiation causes immunosuppression that contri-
butes to skin cancer growth. Photoprotective strategies
initially focused on the more erythemogenic ultraviolet
B. More recently, the relationship of ultraviolet A and
skin cancer has received increased attention. We hy-
pothesized that if ultraviolet A contributes signi¢cantly
to human ultraviolet-induced immune suppression,
then increased ultraviolet A ¢ltration by a sunscreen
would better protect the immune system during ultra-
violet exposure. Two hundred and eleven volunteers
were randomized into study groups and received solar-
simulated radiation, ranging from 0 to 2 minimum
erythema dose, on gluteal skin, with or without sunsc-
reen, 48 h prior to sensitization with dinitrochloroben-
zene. Contact hypersensitivity response was evaluated
by measuring the increase in skin fold thickness of
¢ve graded dinitrochlorobenzene challenge sites on the
arm, 2 wk after sensitization. Clinical scoring using the
North American Contact Dermatitis Group method
was also performed. Solar-simulated radiation dose^
response curves were generated and immune protection
factor was calculated using a nonlinear regression mod-
el. Signi¢cance of immune protection between study
groups was determined with the Mann^Whitney^Wil-
coxon exact test. The sunscreen with high ultraviolet A
absorption (ultraviolet A protection factor of 10, based
on the in vivo persistent pigment darkening method)
and a labeled sun protection factor of 15 demonstrated
better immune protection than the product that had a
low ultraviolet A absorption (ultraviolet A protection
factor of 2) and a labeled sun protection factor of 15.
Nonlinear regression analysis based on skin fold thick-
ness increase revealed that the high ultraviolet A protec-
tion factor sunscreen had an immune protection factor
of 50, more than three times its sun protection factor,
whereas the low ultraviolet A protection factor sunsc-
reen had an immune protection factor of 15, which
was equal to its labeled sun protection factor.This study
demonstrates that ultraviolet A contributes greatly to
human immune suppression and that a broad-spectrum
sunscreen with high ultraviolet A ¢ltering capacity re-
sults in immune protection that exceeds erythema
protection. These results show that high ultraviolet A
protection is required to protect against ultraviolet-
induced damage to cutaneous immunity. Key words:
contact hypersensitivity/immune protection/sunscreen/ultravio-
let light. J Invest Dermatol 121:869 ^875, 2003
S
uppression of the skin’s immune system is known to
be one of the mechanisms by which solar ultraviolet
(UV) radiation induces skin cancer growth (Ullrich,
2002). Sunscreens have been shown to a¡ord protection
against UV-induced immune suppression, although to
date the degree of immune protection a¡orded by these products
falls short of the degree to which they prevent erythema (Ullrich
et al, 1999; Kelly et al, 2003). Because immune suppression occurs
at suberythemogenic doses (Cooper et al, 1992; Kelly et al, 2000),
this level of immune protection is likely to be inadequate. Most
of these studies, however, were conducted using sunscreens that
¢ltered mainly UVB (290^320 nm) and, to some extent, UVAII
(320^340 nm). Recently, there has been a greater awareness re-
garding the immunosuppressive role of UVA (320^400 nm)
(Bestak and Halliday, 1996; LeVee et al, 1997; Damian et al, 1999;
Dumay et al, 2001; Nghiem et al, 2001). For example, Nghiem
et al (2001) demonstrated in mice that UVA e¡ectively suppresses
the elicitation of an established immune response to Candida albi-
cans. Kuchel et al (2002) showed that additional UVA augments
solar-simulated radiation (SSR) induced suppression of elicitation
responses to nickel in nickel-sensitive individuals. LeVee et al
(1997) showed that UVAII (320^340 nm) may have suppressive
e¡ects on the induction of contact sensitization. Other work
focusing on the bene¢t of broad-spectrum coverage (Bestak et al,
1995; Damian et al, 1997; Moyal et al, 1997; Molen et al, 2000;
Moyal and Fourtanier, 2001) and the need for determining a
product’s level of protection in the UVA range (UVA-PF)
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(Fourtanier et al, 2000; Gasparro, 2000; Lim et al, 2000; Nghiem
et al, 2001; Baron and Stevens, 2002) likewise alludes to the con-
tributory role of UVA in photoimmune suppression. Nonethe-
less, the actual e¡ect of UVA protection level on the capacity of
a sunscreen formula to prevent immune suppression has not been
demonstrated in human studies.
This study was performed to determine whether increased
delivery of UVA accompanying SSR would increase immune
suppression and, conversely, whether added protection against
UVA (or high UVA absorption) would increase the immune
protection a¡orded by sunscreens. This was done by evaluating
the e⁄cacy of two commercial sun protection factor (SPF)
15 broad-spectrum sunscreens in preventing UV-induced local
suppression of contact hypersensitivity (CHS) response to dinitro-
chlorobenzene (DNCB) in human subjects.
MATERIALS AND METHODS
All procedures were approved by the Institutional Review Board, Uni-
versity Hospitals of Cleveland Research Institute/Case Western Reserve
University.
Subjects Healthy individuals between 18 and 60 y of age, with
Fitzpatrick skin types IIV, were recruited.Written informed consent was
obtained. Excluded were those on systemic medication (except contra-
ceptive pills) and those with signi¢cant medical and/or dermatologic
history or photosensitivity. The minimum erythema dose (MED) of each
subject was determined and those with an MED of 20^50 mJ per cm2 of
UVB were enrolled. This is equivalent to about 2^7 J per cm2 of total UV
dose (i.e., UVAþUVB) from the full spectrum of SSR. Each quali¢ed
subject was then randomized to a study group.
UV light source SSR was delivered using a 1000 W xenon arc solar
simulator model 6271 (Oriel Instruments, Stratford, CT), with a dichroic
mirror and 81017bis ¢lter (WG320/1.5 mm), producing a spectrum of
290^400 nm. This spectrum as well as the integrated irradiance were
measured with a calibrated Bentham DM 150 double monochromator
spectroradiometer. Irradiance was measured routinely using an IL1700
radiometer (International Light, Newburyport, MA) equipped with a
sensor for UVA (SED 033, UVA ¢lter 19672) and UVB (SED 240, UVB
¢lter 15541) positioned 10 inches from the light source.
Sunscreen products The two sunscreens are commercial US formu-
lations with a labeled SPF of 15.
Absorption spectra of both products were generated by spectro-
radiometric measurements between 290 and 400 nm according to a modi¢ed
Di¡ey method (Di¡ey and Robson, 1989) (Fig 1).
The critical wavelength (lc) was measured according to the Di¡ey
method (Di¡ey et al, 2000). A lc value superior to 370 nm is a criterion
for a broad-spectrum claim. The SPF values were checked using FDA
standard recommendations for SPF determination (Federal Register, 1999)
on 10 volunteers not included in the CHS study. UVA-PF was determined
on 10 other subjects using an in vivo method based on persistent pigment
darkening dose (Moyal et al, 2000).
The high UVA absorption sunscreen (product A) contains avobenzone
(Parsol 1789), octocrylene (Uvinul N 539), and octyl salicylate. The low
UVA absorption sunscreen (product B) contains zinc oxide and octyl
methoxycinnamate (Parsol MCX) (Table I).
MED determination The MED was determined by exposing eight
1 cm areas of gluteal skin to increasing doses of SSR from approximately
1 to 8 J per cm2 of total UVdose. Erythema was assessed 16^24 h later, both
by visual evaluation and by colorimetric measurement using a chromo-
meter (CR-300 Minolta, Tokyo, Japan). Linear regression was applied and
1 MED was calculated according to COLIPA recommendations (Anony-
mous, 1996) as the dose of UV producing an increase in the redness
parameter (da) of þ 2.5.
SPF testing The standard SPF test procedure (COLIPA method)
(Anonymous, 1996) was performed for subjects assigned to study groups
that would undergo sunscreen-protected SSR irradiation. Brie£y, product
was applied over a 48 cm2 area of the buttock at a dose of 2 mg per cm2.
After 15 min, six 1 cm2 areas were then exposed to increasing doses of SSR
ranging from approximately 30 to 150 J per cm2 of total UV. A standard
MED test was simultaneously performed on the unprotected contralateral
gluteal area for comparison. Visual and colorimetric MED readings were
performed 16^24 h postirradiation. SPF was calculated by dividing the
sunscreen-protected MED by the unprotected MED.
SSR irradiation protocol SSRwas delivered over a 1 inch square area
of gluteal skin. For product A, ¢ve groups of subjects were given
unprotected SSR exposures at doses of 0, 0.25, 0.5, 0.75, and 1.0 times their
baseline MED, respectively, whereas seven groups underwent sunscreen
application as described above, followed 15 min later by SSR irradiation
at doses of 0, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0 MED, multiplied by the speci¢c
SPF value obtained from the individual. For product B, three groups
were given unprotected SSR at 0, 0.5, and 0.75 MED, whereas four
groups were given protected SSR exposures at 0, 0.5, 0.75, and 1.0 MED
multiplied by the individual SPF.
DNCB sensitization Sensitization with DNCB was performed on the
SSR-irradiated site 2 d after exposure. The area to be sensitized was ¢rst
evaluated for erythema both visually and by colorimetry. A 48 mL acetone
solution of 0.0625% DNCB (30 mg DNCB) was then applied on the skin
using a ¢lter-paper-lined 1.2 cm Finn chamber, and was kept in place for 48 h.
DNCB challenge Two weeks after sensitization, DNCB challenge was
performed on the contralateral upper inner arm. Twenty microliter
solutions of 0, 3.125, 6.25, 8.75, and 12.5 mg DNCB were applied via ¢ve
¢lter-paper-backed 8 mm Finn chambers that were kept in place for 6 h.
The skin fold thickness (SFT) of the ¢ve challenge sites was measured
before application of the patches and 48 h later using a micrometer
(Mitutoyo, Japan). The total increase in SFT (in millimeters) from the ¢ve
challenge sites was then determined per subject. A clinical score based on
the North American Contact Dermatitis Group (NACDG) systemwas also
recorded for each challenge site as follows: 1, no reaction; 2, macular
erythema; 3, erythema with induration; 4, vesicular/blistering reaction.
The total score from the ¢ve challenge sites was then calculated for each
subject. These two parameters represent the CHS response for each
volunteer. Immune suppression occurs if the immune response observed
in an exposed group is signi¢cantly lower than that of the untreated
unexposed sensitized group.
Data analysis Comparisons between groups were performed by exact
Mann^WhitneyWilcoxon tests, at a two-tailed 5% signi¢cance level. To
determine each product’s immune protection factor (IPF), individual CHS
responses, expressed as (1) total millimeter increase in SFT and (2) total
NACDG score, were plotted against total UV dose delivered in joules per
Figure1. Comparison of the absorption spectra of the two sunsc-
reen products via spectroradiometric measurements between 290
and 400 nm. The spectral curve of product A (high UVA absorption
sunscreen) is higher than that of product B.
Table I. Properties of two commercial SPF 15 sunscreens
Product A Product B
Label SPF 15 15
Actual back US SPF (mm7SD) 18.7873.79 15.4973.91 Not signi¢cant
n¼10 n¼10
UVA-PF in vivo PPD (mm7SD) 10.471.4 2.470.4 po0.01
lc (critical wavelength) 380 nm 372 nm
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square centimeter. Nonlinear regressions were generated from the di¡erent
UV dose^response curves based on the following two-parameter
exponential model:
EQN
where y is response (SFT or NACDG score) and trt equals 0 for
unprotected groups and 1 for sunscreen-treated groups. Associated
estimates for IPF are given with their 95% bilateral con¢dence intervals
(Figs 3, 4). These IPFs are global protection levels, which are not based on
a speci¢c level of biologic response (e.g., minimal or 50% maximal) but
instead are a measure of protection across the entire UV dose^response
range. All analyses were performed on SAS release 8.2 and SPSS release
9.0 statistical software.
RESULTS
Patient characteristics and SPF results A total of 211
volunteers, 85 males and 126 females, with a mean age of 27 y
(range 18^59), completed the study. The Fitzpatrick phototype
(Freedberg et al, 1997) distribution was as follows: I, 18; II, 133;
III, 58; IV, 2; the phototypes were fairly distributed among study
groups. Subjects who were randomized into groups receiving
sunscreen-protected SSR exposure underwent SPF determina-
tion. This revealed an average SPF value of 15.473.4 SD (range
7.6^23.6) for product A (n¼ 57) and 9.972.3 SD (range 6.0^15.7)
for product B (n¼ 30). The wide range of values obtained
highlights the need for testing individual SPF.
Irritancy and positive controls To test the irritancy
component of the allergen DNCB, a total of 18 volunteers
underwent DNCB elicitation on the arm without prior
sensitization. This yielded a mean SFT increase, in millimeters,
of 0.3170.19 SD and a mean clinical score of 5.6771.03 SD,
based on the NACDG system. In contrast, a total of 21 subjects
who underwent DNCB sensitization on the buttock 2 wk prior
to DNCB elicitation on the arm demonstrated a mean SFT
increase of 2.9871.32 SD and a mean NACDG score of 12.387
2.84 SD. Statistical analysis via exact Mann^WhitneyWilcoxon
test revealed a signi¢cant di¡erence between the irritancy and
positive control groups based on both SFT and NACDG score
(po0.01).
Higher degree of immune suppression was obtained with
increased UVA exposure The immune protection a¡orded by
each product was compared at two suberythemogenic doses (0.5
and 0.75 MED) (Fig 2). Results indicate that the product with
high UVA absorption a¡orded a signi¢cantly higher degree of
immune protection than the product with low UVA absorp-
tion. Using Mann^WhitneyWilcoxon exact tests, signi¢cant
immune suppression among unprotected subjects was observed
for both endpoints (SFT and NACDG) at 0.5 MED (p¼ 0.001).
Whereas subjects who underwent SSR exposure after applying
the low UVA absorption sunscreen demonstrated signi¢cant
immune suppression at the 0.5 MEDSPF dose and the 0.75
MEDSPF dose (po0.05), those who received less UVA
irradiation by using the sunscreen with high UVA absorption
did not demonstrate signi¢cant immune suppression at these
two doses (p40.4) and even at the dose of 1 MEDSPF
(p40.1) for SFT.
Although it may seem surprising that the mean CHS response
of the product-A-protected subjects in the 0.5 MED group
exceeded that of the unirradiated controls, this may be explained
by the fact that the mean is sometimes tilted in favor of extremely
high values such as the SFT readings in millimeters obtained
from some subjects who had very strong reactions. This
disparity in CHS response was observed less when clinical
scoring was used because there is an upper limit of 4 in the
NACDG scale.
High UVA ¢ltration protects against immune suppression
more than erythema To calculate the sunscreen’s level of
e⁄cacy against immune suppression (i.e., IPF), CHS responses
based on SFT increase and clinical score were plotted against
total UV dose delivered in joules per square centimeter (Figs 3,
4). Using a nonlinear regression model, the sunscreen with high
UVA absorption revealed an IPF of 50, based on SFT increase.
This value is more than three times the labeled SPF of 15.
Clinical scoring resulted in a lower IPF value of 37, which is still
more than twice the labeled SPF. The low UVA absorption
sunscreen’s IPF was equal to its labeled SPF of 15 based on SFT
increase, and to 11 based on clinical scoring. To illustrate the
immune protection bene¢t of high UVA protection on SFT,
hypothetical dose^response curves were generated from the
regression model of the immune responses of the unprotected
subjects assuming that IPF was twice the SPF (i.e., 30) and three
times the SPF (i.e., 45) (Fig 5). The resultant curves fall below the
actual dose^response curve of product-A-protected subjects,
graphically demonstrating and validating that the IPF of the
high UVA absorption sunscreen is indeed more than twice and
may be three times its SPF.
DISCUSSION
Skin cancer is the most common type of malignancy a¡ecting
white populations worldwide, and its incidence continues to
increase in alarming proportions (Diepgen and Mahler, 2002).
Because of the crucial role of immune suppression in the process
of cutaneous carcinogenesis (Ullrich, 2002), protection against
Figure 2. Characteristics of sunscreens tested. Mean CHS response at
0.5 and 0.75 MED doses were compared for unprotected, high UVA ab-
sorption sunscreen-protected, and low UVA absorption sunscreen-pro-
tected groups, based on SFT increase (a) and NACDG score (b). Using
exact Mann^WhitneyWilcoxon tests, signi¢cant CHS suppression was
not obtained at either dose among groups protected by the high UVA ab-
sorption sunscreen. Signi¢cant CHS suppression was observed in the
groups that used a low UVA absorption sunscreen starting at 0.5 MED.
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UV-induced immunosuppression has been the object of numer-
ous research studies performed both in animal and human mod-
els (Bestak et al, 1995; Whitmore and Morrison, 1995; Damian
et al, 1997; Moyal et al, 1997; Roberts and Beasley, 1997a; 1997b; Serre
et al, 1997). Indeed, methods to prevent photoimmune suppression
must be considered of high priority in the global campaign on
skin cancer prevention.Whereas the immunosuppressive and carci-
nogenic potential of the more erythemogenic UVB spectrum is
well established, less is known about UVA, even though UVA
comprises 90%^95% of terrestrial UV radiation and is more pene-
trating (e.g., through glass windows) than UVB. More recent data
suggest that the less erythemogenic UVA spectrum is much more
involved in the process of immune suppression and carcinogenesis,
including melanoma formation, than was originally appreciated
(Setlow et al, 1993; Drobetsky et al, 1995; Bestak and Halliday, 1996;
Kielbassa et al, 1997; Kvam and Tyrrell, 1997; Iwai et al, 1999;
Nghiem et al, 2001; Wang et al, 2001). These data have led to the
growing emphasis on broad-spectrum coverage and the necessity
to evaluate a product’s level of protection in the UVA range
(UVA-PF), aside from its SPF.
Although it is known that sunscreens could protect from detri-
mental e¡ects of UV other than erythema, our study demon-
strates for the ¢rst time in human subjects that a broad-spectrum
sunscreen with high UVA absorption could in fact a¡ord signi¢-
cant protection against UV-induced CHS suppression, to a
degree that greatly exceeds its capacity to prevent erythema (i.e.,
IPF4SPF). Because erythema remains the only well-de¢ned bio-
logic endpoint accepted by regulatory authorities for evaluating
sunscreen e⁄cacy (Federal Register, 1999), the SPF is often used
in photobiologic studies for comparison with a novel entity such
as IPF. Despite a lack of consensus regarding the standard model
for determining IPF, our data clearly indicate that product A,
with high absorption of both UVA and UVB, provided immune
protection that is more than three times its SPF (Fig 5) and that
such level of immune protection was de¢nitely not observed
with low ¢ltration of UVA, despite equally high ¢ltration of
UVB, using product B, another broad-spectrum sunscreen with
a similar SPF but with a lower UVA-PF. This con¢rms that a
high UVA absorptive capacity is crucial in order for a product to
optimally protect against immune suppression, which, in turn,
indicates that UVA signi¢cantly contributes to local suppression
of contact sensitivity induction in humans.
These ¢ndings obtained from in vivo human immune responses
are supported by previous work focusing on UVA-induced
Figure 3. CHS responses via SFT increase (a) and
NACDG score (b) were plotted against total UV
dose delivered for the high UVA absorption
sunscreen. Nonlinear regression analysis revealed
higher IPF compared to the low UVA absorption
sunscreen (Fig 4). Sunscreen-treated individuals
are represented by ( ) and nontreated ones by (}).
Estimated IPF and associated con¢dence intervals
are indicated in boxes. The UVR dose^response
curves for suppression of CHS are represented in
blue for nontreated according to the equation
y¼ exp(aþ bdose) and in red for sunscreen-treated
according to the equation y¼ exp(aþ bdose/IPF),
with their con¢dence interval limits (dashed lines).
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changes within cells and cellular components that a¡ect immu-
nologic responsiveness. DNA is considered a major molecular tar-
get of UV radiation, in the induction of immune
suppression. DNA damage in the form of pyrimidine dimers has
been observed in human skin after UVA irradiation at a dose of 1
MED (Burren et al, 1998). Antigen presentation is altered by UVA
(5^20 J per cm2) via suppression of costimulatory molecule
expression on Langerhans cells in vitro (Iwai et al, 1999). The same
group of researchers likewise showed in mice that UVA (130 J per
cm2) causes suppression of lymph node cell proliferation in
response to trinitrochlorobenzene. These e¡ects were prevented
by glutathione application, suggesting involvement of reactive
oxygen species. Indeed, oxidative damage, another mechanism
associated with photoimmune suppression, has been found to
occur most e⁄ciently within the UVA spectrum (Kielbassa et al,
1997; Kvam and Tyrrell, 1997). Dumay et al (2001) found that in
vivo exposure of human skin to UVA1 (30 and 60 J per cm2)
results in decreased allogeneic CD4þ T cell proliferation. This
was partially prevented by application of sunscreen containing
7% octocrylene and 3% butylmethoxydibenzoylmethane;
however, no data on actual in vivo human responsiveness was
provided. Furthermore, the inability to fully protect against
UV-induced suppression of in vitro antigen-presenting cell func-
tion was attributed to the product’s low UVA-PF (370.2).
Epidemiologic studies on sunscreen use and the occurrence of
melanoma have shown an increased incidence of this cancer
among individuals who used sunscreens (Garland et al, 1993; Au-
tier et al, 1995), although there is much controversy in the litera-
ture regarding such correlation. Our results suggest that the lack
of adequate UVA ¢lters in the vast majority of sunscreens marketed
in the 1970s and 1980s permitted the immunosuppressive and
other harmful biologic e¡ects of UVA to take place but prevented
Figure 4. CHS responses via SFT increase (a) and
NACDG score (b) were plotted against total UV
dose delivered for the low UVA absorption sunsc-
reen.Nonlinear regression analysis revealed higher IPF
for the high UVA absorption sunscreen (Fig 3) com-
pared to the low UVA absorption sunscreen. Sunsc-
reen-treated individuals are represented by ( ) and
nontreated ones are represented by (}). Estimated IPF
and associated con¢dence intervals are indicated in
boxes. The UVR dose^response curves for suppression
of CHS are represented in blue for nontreated accord-
ing to the equation y¼ exp(aþ b dose) and in red
for sunscreen-treated according to the equation
y¼ exp(aþ bdose/IPF), with their con¢dence inter-
val limits (dashed lines).
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UVB-induced changes, such as erythema, that provide warning
that excessive exposure has occurred, thereby favoring melanoma
development.
In summary, this study has shown that in human subjects UVA
contributes signi¢cantly to SSR-induced immune suppression
and the use of a broad-spectrum sunscreen with a su⁄ciently
high UVA-PF results in protection against SSR-induced CHS
suppression to a degree that exceeds the product’s capacity to pre-
vent erythema, and at a level that is signi¢cantly greater than the
immune protection obtained when a product of equal SPF but a
much lower UVA-PF was used. These results de¢nitively demon-
strate the etiologic role of UVA in immune suppression and con-
¢rm the growing evidence regarding the role of UVA in
carcinogenesis. In the global attempt to promote sun protective
measures and prevent skin cancer, it is critical to continually edu-
cate the public regarding the risks of excessive exposure to UVA
(e.g., tanning beds), and to emphasize the need to use broad-spec-
trum sunscreens with adequate levels of UVA protection if sun
avoidance is not possible.
This study was supported by L’OreŁ al Recherche, Clichy, France.
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